The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | An insight into sequencing bispecifics and CAR-T in multiple myeloma
In this video, Peter Forsberg, MD, Colorado Blood Cancer Institute, Denver, CO, shares his view on the current approach to sequencing bispecific antibodies and CAR T-cell therapy in multiple myeloma (MM), emphasizing the importance of treating patients with a T-cell–based therapy as soon as possible. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s a complex area. You know, right now, the myeloma field continues to evolve very rapidly. You know, we are balancing the, you know, anticipated benefit from CARs and bispecifics for patients. And, you know, I do think that the best way to approach sequencing is to do it deliberately, you know, to discuss management with providers who administer CAR-Ts as you’re making that decision for patients...
It’s a complex area. You know, right now, the myeloma field continues to evolve very rapidly. You know, we are balancing the, you know, anticipated benefit from CARs and bispecifics for patients. And, you know, I do think that the best way to approach sequencing is to do it deliberately, you know, to discuss management with providers who administer CAR-Ts as you’re making that decision for patients. I do think that right now, I don’t think that there’s a wrong answer. You know, I think we have plenty of thoughts and opinions about, you know, best approaches to sequencing. But I think more important than any of that is getting these patients to a T-cell-based therapy, not pushing that too far down the road because the benefit with these modalities, both bispecific T-cell engagers and CARs, is profound. And so patients, we need to find paths. I think finding a path may be more important than spending too much time wondering if you’re on exactly the right path.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
